

# Dysplastic Nevus Syndrome

[View the current Dysplastic Nevus Syndrome InDepth page on BioPortfolio.com \(PDF\)](#)  
([http://www.bioportfolio.com/indepth/Dysplastic\\_Nevus\\_Syndrome.html](http://www.bioportfolio.com/indepth/Dysplastic_Nevus_Syndrome.html)) - Regularly Updated.

## Recent Publications on Dysplastic Nevus Syndrome:



- [Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi \("Spark's" nevi\).](#)  
*BACKGROUND: Nevi with cytologic characteristics of Spitz nevus and...* 10th November, 2009  
Department of Dermatology, Yale University School of Medicine, New Haven,- J Cutan Pathol. 2009 Oct;36(10):1063-8. Epub 2009 Jan 27. ([DOI Direct Link](#))
- [Childhood melanoma.](#)  
*Pediatric melanoma is rare but increasing in incidence. Because early...* 3rd November, 2009  
Department of Dermatology, University of Connecticut Health Center, 263- Clin Dermatol. 2009 Nov-Dec;27(6):529-36. ([DOI Direct Link](#))
- [The reticular point of view in dermatoscopy.](#)  
*BACKGROUND: Different dermatoscopic algorithms have been developed to...* 9th October, 2009  
Department of Dermatology and Plastic Surgery, University of Rome- J Am Acad Dermatol. 2009 Oct;61(4):605-10. Epub 2009 Aug 22. ([DOI Direct Link](#))
- [Early diagnosis of melanotic melanoma based on laser-induced melanin fluorescence.](#)  
*Because of the increasing incidence of skin cancer, interest in using the...* 23rd September, 2009  
Praxis fur Dermatologie, Kurfurstendamm 139, Berlin 10711, Germany.- J Biomed Opt. 2009 May-Jun;14(3):034033. ([DOI Direct Link](#))
- [WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.](#)  
*OBJECTIVE: Recent studies indicate that WT1 and Bcl2 protein are detected...* 21st August, 2009  
Department of Neuropathology and Ophthalmic Pathology, Armed Forces- Arch Ophthalmol. 2009 Aug;127(8):964-9. ([DOI Direct Link](#))
- [Nucleolin protein expression in cutaneous melanocytic lesions.](#)  
*BACKGROUND: Nucleolin is a major nucleolar argyrophilic protein involved...* 20th August, 2009  
Department of Human Pathology and Oncology, Section of Pathological- J Cutan Pathol. 2009 Jun;36(6):637-46. ([DOI Direct Link](#))
- [Neurofibromatosis type 1 associated with dysplastic nevus syndrome.](#)  
*Neurofibromatosis type 1 (NF-1) is an autosomal dominant disorder that...* 15th July, 2009  
University Department of Dermatology and Venereology, Zagreb University- Acta Dermatovenerol Croat. 2009;17(2):118-22.
- [Novel variants of muscle calpain 3 identified in human melanoma cells: cisplatin-induced changes in vitro and differential expression in melanocytic lesions.](#)  
*Calpains are cysteine proteases comprising members ubiquitously expressed...* 27th June, 2009

Department of Physiopathology, Experimental Medicine and Public Health,- Carcinogenesis. 2009 Jun;30(6):960-7. Epub 2009 Apr 21. ([DOI Direct Link](#))

- [Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.](#)  
*Dysregulation of cell adhesion molecules is associated with progression of...*24th June, 2009  
Dept of Dermatology and Allergology, Ruhr-University Bochum, Germany.- Am J Clin Pathol. 2009 Jun;131(6):782-7. ([DOI Direct Link](#))
- [Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.](#)  
*AIMS: Glucose-regulated protein 78 (GRP78) is a protein translated in...*16th June, 2009  
Department of Anatomical Pathology, Royal Prince Alfred Hospital, Sydney,- Histopathology. 2009 Mar;54(4):462-70. ([DOI Direct Link](#))
- [Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis.](#)  
*A 58-year-old man presented in 2001 with dysplastic nevus syndrome with at...*22nd May, 2009  
Department of Dermatology, University of Tübingen, Germany.- J Dtsch Dermatol Ges. 2009 Sep;7(9):773-5. ([DOI Direct Link](#))
- [Expression pattern of anti-apoptotic protein survivin in dysplastic nevi.](#)  
*The anti-apoptotic protein survivin was detected in a panel of 27...*20th May, 2009  
Institute of Histology and Embryology, Jessenius Faculty of Medicine,- Neoplasma. 2009;56(2):130-5.
- [Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.](#)  
*BACKGROUND: Markers identifying premalignant and malignant melanocytic...*9th May, 2009  
Department of Dermatology and Allergology, Ruhr-University Bochum,- J Am Acad Dermatol. 2009 May;60(5):808-13. ([DOI Direct Link](#))
- [Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.](#)  
*Neoplastic melanocytes may exhibit certain differentiation characteristics...*29th April, 2009  
Department of Dermatology and Allergology, Ruhr-University Bochum,- Am J Clin Pathol. 2009 May;131(5):710-4. ([DOI Direct Link](#))
- [The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis.](#)  
*PURPOSE: To study the relationship between cutaneous and iris nevi with...*21st March, 2009  
Harvard School of Public Health, Boston, Massachusetts, USA.- Ophthalmology. 2009 Mar;116(3):536-543.e2. Epub 2009 Jan 22. ([DOI Direct Link](#))

## Dysplastic Nevus Syndrome Patents:



- 6124303- [Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-\(2-N-aloxyphenyl\) purin-6-ones](#)
- 6232312- [Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acids](#)
- 6239136- [Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives](#)
- 6262059- [Method of treating a patient having precancerous lesions with quinazoline derivatives](#)
- 6268372- [Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones](#)

- 6300346- [Indenyl hydroxamic acids, \(hydroxy\) ureas and urethanes for treating patients with precancerous lesions](#)
- 6348032- [Method of inhibiting neoplastic cells with benzimidazole derivatives](#)
- 6358992- [Method of inhibiting neoplastic cells with indole derivatives](#)
- 6369092- [Method for treating neoplasia by exposure to substituted benzimidazole derivatives](#)
- 6380206- [Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives](#)
- 6391885- [Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives](#)
- 6231888- [Local delivery of non steroidal anti inflammatory drugs \(NSAIDS\) to the colon as a treatment for colonic polyps](#)
- 6211220- [Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives](#)
- 6211177- [Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives](#)
- 6130053- [Method for selecting compounds for inhibition of neoplastic lesions](#)
- 6133271- [Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives](#)
- 6156528- [Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia](#)
- 6160003- [1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia](#)
- 6166053- [Substituted condensation products of N-benzyl-3-idenylacetamides with heterocyclic aldehydes for neoplasia](#)
- 6180629- [\[4,5\]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substituents in position one for the treatment of neoplasia](#)
- 6187779- [Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives](#)
- 6200771- [Method of using a novel phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia](#)
- 6200980- [Method of treating a patient having precancerous lesions with phenyl purinone derivatives](#)
- 6207666- [Method for treating a patient having precancerous lesion with 4-phenylphthalazine derivatives](#)
- 6403831- [Substituted benzylidene indenyl formamides, acetamides and propionamides](#)
- 6410584- [Method for inhibiting neoplastic cells with indole derivatives](#)
- 6610854- [Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia](#)
- 6642221- [Vanadium compounds as anti-proliferative agents](#)
- 6689561- [Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment](#)
- 6689864- [Cyclin dependent kinase 4 inhibitor](#)
- 6878388- [Vanadium compounds for treating proliferative cell disorders](#)
- 6906064- [Method for treating a patient with neoplasia using Iressa](#)
- 6974672- [Gene amplification in cancer](#)
- 7115647- [Method of inhibiting neoplastic cells with indole derivatives](#)
- 7138146- [Acrochordon alleviation](#)
- 7297480- [Method for detection of melanoma](#)
- 6569638- [Method for screening compounds for the treatment of neoplasia](#)
- 6562830- [Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives](#)
- 6555547- [Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative](#)
- 6420410- [Method for treating neoplasia by exposure to N,N'-substituted benzimidazol-2-ones](#)
- 6426349- [Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia](#)
- 6432950- [Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives](#)
- 6433025- [Method for retarding and preventing sunburn by UV light](#)

- 6440981- [Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones](#)
- 6455703- [1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia](#)
- 6479520- [Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives](#)
- 6486155- [Method of inhibiting neoplastic cells with isoquinoline derivatives](#)
- 6486158- [\[4,5\]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia](#)
- 6500610- [Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds](#)
- 7381427- [Seborrheic keratosis treatment](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

